Chempartner Pharmatech issues a notice of abnormal fluctuations in stock trading. The company recently received the "Decision on Issuing a Warning Letter to Chempartner Pharmatech Co., Ltd., Zeng Xianwei, Woo Swee Lian, Zhang Jiguo, Wang Kui, Cha Yinqun, and Xu Jian, by the Guangdong Regulatory Bureau of the China Securities Regulatory Commission" ([2024] No. 145) (referred to as the "Warning Letter"), requiring the company to correct the issues raised in the Warning Letter. The company will, in accordance with relevant regulations such as "Enterprise Accounting Standard No. 28 - Accounting Policies, Changes in Accounting Estimates and Errors Correction" and "Rules for Disclosure of Financial Information of Companies Issuing Securities No. 19 - Correction of Financial Information and Related Disclosures", correct and revise the 2022 and 2023 annual reports already disclosed by the company. At present, the company is communicating with the auditing firm regarding corrections to previous annual reports. For specific and accurate financial data, please refer to the relevant reports corrected by the company in subsequent disclosures.